Last reviewed · How we verify
BR-A-657
At a glance
| Generic name | BR-A-657 |
|---|---|
| Also known as | Fimasartan, 20, 60, 120, 240, 360, 480mg |
| Sponsor | Boryung Pharmaceutical Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fed Conditions (PHASE1)
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- An OS to Evaluate Effectiveness and Safety of Fixed-dose Combinations of FMS/AML or FMS/AML/HCTZ
- A Combination Drug Including Fimasartan and Statins in Patients With Hypertension and Dyslipidemia
- Fimasartan Optimal Reduction Targeting Elevated Blood Pressure: the FORTE Study
- A Study to Evaluate the Efficacy and Safety of BR1015 Combination Therapy (PHASE3)
- A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary Hypercholesterolemia (PHASE3)
- Effect of Fimasartan on Extended RAS and Vascular Functions in Patients With Type 2 Diabetes and Hypertension (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BR-A-657 CI brief — competitive landscape report
- BR-A-657 updates RSS · CI watch RSS
- Boryung Pharmaceutical Co., Ltd portfolio CI